{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61","upperLimit":"82","value":"73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Primary clinical response rate is defined as the proportion of patients with complete response or partial response at their primary sites after induction therapy. Response status for the primary site was classified by clinical examination using endoscopy. If, however, the clinical response status of the primary was unclear based on endoscopy, then the CT or MRI (required at the end of induction) was used to determine status of the primary. If clinical and radiological evaluation of the primary was unclear, a biopsy was considered at the discretion of the treating physician.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cisplatin IV on day 1 and paclitaxel IV and cetuximab IV on days 1, 8, and 15. Treatment repeats every 21 days for 3 courses. Patients then undergo evaluation of response to induction therapy. Patients with a CR at the primary tumor site proceed to group 1 of concurrent low-dose IMRT and cetuximab. Patients with a PR or SD at the primary tumor site or those with grossly positive disease at the primary tumor site proceed to group 2 of concurrent standard dose IMRT and cetuximab.","id":"OG000","title":"Eligible and Treated Patients"}],"paramType":"NUMBER","populationDescription":"eligible and treated patients","reportingStatus":"POSTED","timeFrame":"assessed within 14 days after delivery of the third cycle of induction therapy","title":"Primary Clinical Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}